Release Notes: Version 20200207
About this release
This release (version 20200207) provides the latest updates to the Canadian Clinical Drug Data Set in English and French. There is a separate InfoScribe location for the French supporting documents including the French Release Notes that can be found here.
There is no change to the Editorial Guidelines and the Technical Specification in this release.
The Canadian Clinical Drug Data Set is available for browsing and download via the Infoway Terminology Gateway.
Supporting general information can be found on Infoway Canadian Clinical Drug Data Set InfoCentral page.
General Notes
The following files are available as full release files within this version:
- Manufactured Product,
- Non-proprietary Therapeutic Product,
- Therapeutic Moiety,
- Manufactured Product-Non-proprietary Therapeutic Product-Therapeutic Product Relationship, in English (MP-NTP-TM Relationship),
- Manufactured Product-Non-proprietary Therapeutic Product-Therapeutic Product Relationship, in French (Relation PM-PTC-FT),
- Special Groupings,
- Coded Attribute, and
- Device Non-proprietary Therapeutic Product.
The "Full" release contains one entry for every concept that has ever been released and new content added for that release. New content added for a specific release may at times include “Inactive” content.
NOTE: The “Delta" release which is intended to contain only those concepts that have been added or changed since the previous release will be considered for a future enhancement at a later date.
This release reflects additions and changes that have occurred in DPD since the last CCDD release.
NTP
There is one new deprecated NTP concept with this release. The concept is no longer in use since the dosage form of the corresponding MP changed in DPD from solution to syrup.
| ntp_code | ntp_formal_name | ntp_fr_description | Type of change |
|---|---|---|---|
| 9013672 | codeine phosphate 3.3 mg per 5 mL and guaifenesin 100 mg per 5 mL and pseudoephedrine hydrochloride 30 mg per 5 mL oral solution | phosphate de codéine 3,3 mg par 5 mL et guaïfénésine 100 mg par 5 mL et chlorhydrate de pseudoéphédrine 30 mg par 5 mL solution orale | Concept deprecated |
MP
mp_code February Release | mp_formal_name February Release | mp_fr_description February Release | mp_formal_name January Release | French mp_formal_name January Release |
|---|---|---|---|---|
| 02172917 | CALMYLIN PSE WITH CODEINE (codeine phosphate 3.3 mg per 5 mL and guaifenesin 100 mg per 5 mL and pseudoephedrine hydrochloride 30 mg per 5 mL syrup) TEVA CANADA LIMITED | CALMYLIN PSE WITH CODEINE (phosphate de codéine 3,3 mg par 5 mL et guaïfénésine 100 mg par 5 mL et chlorhydrate de pseudoéphédrine 30 mg par 5 mL sirop) TEVA CANADA LIMITED | CALMYLIN PSE WITH CODEINE (codeine phosphate 3.3 mg per 5 mL and guaifenesin 100 mg per 5 mL and pseudoephedrine hydrochloride 30 mg per 5 mL oral solution) TEVA CANADA | CALMYLIN PSE WITH CODEINE (phosphate de codéine 3,3 mg par 5 mL et guaïfénésine 100 mg par 5 mL et chlorhydrate de pseudoéphédrine 30 mg par 5 mL solution orale) TEVA CANADA LIMITED |
Questions, Concerns, Changes
Questions and concerns and suggestions for future consideration are welcomed and should be sent by e-mail at [email protected]